Vol. 2 No. 5 (2008) | Hematology Meeting Reports

Current Issue

Vol. 2 No. 5 (2008)

23 June 2009

View this Issue

Vol. 2 No. 5 (2008)

Published: 23 June 2009

New Drugs in Hematology, Bologna, Italy 5-7 October 2008

Abstracts

Myelodysplastic syndromes

M Cazzola

https://doi.org/10.4081/hmr.v2i5.717

223

PDF: 131
- PDF
Organ damage and iron overload

E Angelucci, C Cogoni, M Pettinau, F Pilo, C Targhetta, F Zacchedu

https://doi.org/10.4081/hmr.v2i5.718

309

PDF: 1428
- PDF
Progress in the management of iron overload in erytrocyte disorders

MD Cappellini, E Cassinerio, L Zanaboni, G Fabio, P Pattoneri

https://doi.org/10.4081/hmr.v2i5.719

250

PDF: 1729
- PDF
Ph positive-leukemias

F Guilhot, L Roy, J Guilhot, PJ Saulnier, JM Gombert, A Turhan

https://doi.org/10.4081/hmr.v2i5.720

189

PDF: 184
- PDF
Thyrosin kinase inhibitors: nilotinib

F Castagnetti, F Palandri, G Gugliotta, A Poerio, M Amabile, S Soverini, G Martinelli, M Baccarani, G Rosti

https://doi.org/10.4081/hmr.v2i5.721

389

PDF: 476
- PDF
New drugs to overcome meccanisms of resistance in Ph+ leukemia: bosutinib

G Martinelli, I Iacobucci, D Cilloni, P Giannoulia, S Soverini, PP Piccaluga, C Papayannidis, S Paolini, C Terragna

https://doi.org/10.4081/hmr.v2i5.722

243

PDF: 243
- PDF
Peripheral T-cell lymphomas

SA Pileri, C Agostinelli, C Campidelli, F Bacci, E Sabattini, A Pileri Jr, PP Piccaluga

https://doi.org/10.4081/hmr.v2i5.723

282

PDF: 641
- PDF
Histone deacetylase inhibitors: SAHA (Vorinostat). A treatment option for advanced cutaneous T-cell lymphoma

M Duvic

https://doi.org/10.4081/hmr.v2i5.724

268

PDF: 2382
- PDF
A Phase II international, multicenter study of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma

MG Bernengo, F Vanaclocha, M Duvic, T Kuzel, F Kerdel, L Pinter-Brown, A Bosly, C Okada, D Breneman, PL Zinzani, J Becker, L Hughey, M Ardaiz, J Zain, L Zhang

https://doi.org/10.4081/hmr.v2i5.725

205

PDF: 219
- PDF
Chronic lymphocytic leukemia

F Caligaris-Cappio

https://doi.org/10.4081/hmr.v2i5.727

225

PDF: 2586
- PDF
Monoclonal antibodies (update): CD20, rituximab

C Hagenbeek

https://doi.org/10.4081/hmr.v2i5.728

215

PDF: 149
- PDF
90Y-ibritumumab tiuxetan (Zevalin)

PL Zinzani

https://doi.org/10.4081/hmr.v2i5.729

247

PDF: 379
- PDF
Update of alemtuzumab in the treatment of chronic lymphocytic leukaemia

C Dearden

https://doi.org/10.4081/hmr.v2i5.731

200

PDF: 244
- PDF
Immunotherapy with epratuzumab in B-cell non-Hodgkin’s lymphoma

P Martin, D Goldenberg, JP Leonard

https://doi.org/10.4081/hmr.v2i5.732

166

PDF: 384
- PDF
New agents for the treatment of acute myeloid leukemia: gemtuzumab ozogamicin

S Amadori

https://doi.org/10.4081/hmr.v2i5.733

185

PDF: 577
- PDF
Update on galiximab: anti-CD80 monoclonal antibody

MS Czuczman

https://doi.org/10.4081/hmr.v2i5.734

246

PDF: 275
- PDF
CMC-544 (inotuzumab ozogamicin): A CD22-targeted immunoconjugate of calicheamicin

JF DiJoseph, K Khandke, MM Dougher, DY Evans, DC Armellino, PR Hamann, NK Damle

https://doi.org/10.4081/hmr.v2i5.735

689

PDF: 2497
- PDF
Zanolimumab (HuMax-CD4®), a fully human monoclonal antibody in clinical development for cutaneous T-cell lymphoma

C Assaf

https://doi.org/10.4081/hmr.v2i5.736

296

PDF: 366
- PDF
Monoclonal antibodies (novel): humax-CD20, ofatumumab

A Hagenbeek

https://doi.org/10.4081/hmr.v2i5.737

214

PDF: 242
- PDF
Lumiliximab in chronic lymphocytic leukemia

TS Lin

https://doi.org/10.4081/hmr.v2i5.738

215

PDF: 474
- PDF
Bevacizumab as an anti-VEGF strategy in lymphoma

SJ Horning

https://doi.org/10.4081/hmr.v2i5.739

300

PDF: 212
- PDF
Individualizing therapy for the hematologic malignancies: the stuff of genes and dreams

BD Cheson

https://doi.org/10.4081/hmr.v2i5.741

229

PDF: 300
- PDF
Aurora kinase inhibitor: AS703569

A Gianella-Borradori

https://doi.org/10.4081/hmr.v2i5.742

235

PDF: 310
- PDF
From cell biology to therapy: lenalidomide in untreated multiple myeloma

A Palumbo, P Falco, F Gay, V Magarotto, F Patriarca, C Nozzoli, M Boccadoro

https://doi.org/10.4081/hmr.v2i5.744

210

PDF: 251
- PDF
HuMax-CD38, a new human CD38 monoclonal antibody, effectively mediates killing of multiple myeloma and plasma cell leukemia cells

PWHI Parren

https://doi.org/10.4081/hmr.v2i5.740

496

PDF: 630
- PDF
Pha-739358: a pan-aurora kinase inhibitor

R Paquette, N Shah, C Sawyers, G Martinelli, J Nicoll, M Chalukya

https://doi.org/10.4081/hmr.v2i5.743

273

Untitled: 0

PDF: 456
- PDF
From cell biology to therapy: lenalidomide in relapsed/refractory multiple myeloma

P Richardson, T Hideshima, C Mitsiades, R Schlossman, J Laubach, I Ghobrial, N Raje, N Munshi, K Anderson

https://doi.org/10.4081/hmr.v2i5.745

206

PDF: 324
- PDF
Bendamustine is a hybrid antimetabolite and alkylating agent offering new therapeutic options for the treatment of non-Hodgkin lymphomas

A Dreyling

https://doi.org/10.4081/hmr.v2i5.749

382

PDF: 462
- PDF
From cell biology to therapy: forodesine

M Duvic

https://doi.org/10.4081/hmr.v2i5.746

420

PDF: 791
- PDF
Flavopiridol (alvocidib) in chronic lymphocytic leukemia

TS Lin, B Fischer, KA Blum, M Brooker-McEldowney, ME Moran, LA Andritsos, JM Flynn, MA Phelps, JT Dalton

https://doi.org/10.4081/hmr.v2i5.747

343

PDF: 837
- PDF
mTOR inhibitors for the treatment of lymphoma

TE Witzig

https://doi.org/10.4081/hmr.v2i5.748

223

PDF: 361
- PDF
Multiple myeloma

J San Miguel

https://doi.org/10.4081/hmr.v2i5.750

166

PDF: 121
- PDF
Proteasome inhibitors: bortezomib in multiple myeloma

M Cavo, MC Pallotti, L Pantani, A Petrucci, A Brioli, C Terragna, N Testoni, G Marzocchi, S Durante, M Ceccolini, G Perrone, P Tacchetti, E Zamagni, P Tosi, M Baccarani

https://doi.org/10.4081/hmr.v2i5.751

197

PDF: 233
- PDF
Bortezomib in lymphomas

A Goy

https://doi.org/10.4081/hmr.v2i5.752

208

PDF: 180
- PDF
Proteasome inhibitors: beyond NFKB inhibition alone and the emerging role of combination therapy in the treatment of multiple myeloma

P Richardson, C Mitsiades, J Laubach, C Conant, T Hideshima, D Chauhan, R Schlossman, I Ghobrial, N Munshi, KC Anderson

https://doi.org/10.4081/hmr.v2i5.753

424

PDF: 263
- PDF
Novel proteasome inhibitors

P Tosi, MC Pallotti, L Pantani, A Petrucci

https://doi.org/10.4081/hmr.v2i5.754

225

PDF: 350
- PDF
Decitabine in myeloid malignancies

HI Saba

https://doi.org/10.4081/hmr.v2i5.755

197

PDF: 854
- PDF
J-L. Harousseau Tipifarnib in hematologic malignancies

JL Harousseau

https://doi.org/10.4081/hmr.v2i5.756

189

PDF: 265
- PDF
Is there a role for immunotherapy in Hodgkin’s disease?

B Böll, A Engert

https://doi.org/10.4081/hmr.v2i5.757

181

PDF: 586
- PDF
New agents for the treatment of acute myeloid leukemia: midostaurin

S Amadori

https://doi.org/10.4081/hmr.v2i5.760

241

PDF: 905
- PDF
Lestaurtinib as a FLT3 inhibitor

AK Burnett

https://doi.org/10.4081/hmr.v2i5.761

177

PDF: 189

Untitled: 0
- PDF

© PAGEPress 2008-2025 • PAGEPress^® is a registered trademark property of PAGEPress srl, Italy • VAT: IT02125780185 • Privacy